Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247777 | 0.85 | NAPRT (0.53) | GRM5NAPRTALDH1A1MEN1KMT2A | |
| SCHEMBL5429605 | 0.81 | GRM5 (0.54) | GRM5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL998975 | 0.81 | GRM5 (0.54) | GRM5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL333999 | 0.80 | NAPRT (0.60) | NAPRTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL31606802 | 0.80 | NAPRT (0.60) | NAPRTALDH1A1MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL4342515 | 0.79 | GRM5 (0.42) | GRM5NAPRTALDH1A1MEN1KMT2A | |
| SCHEMBL5312194 | 0.79 | SMN1; SMN2 (0.55) | GRM5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL5420477 | 0.79 | HPGD (0.53) | GRM5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL12844304 | 0.79 | GRM5 (0.52) | GRM5ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4061969 | 0.79 | NAPRT (0.50) | GRM5NAPRTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1966144-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007071358-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-22 | — | — | US | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-6303790-B1 | REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND | HOFFMAN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1103546-A1 | Process for preparation of pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
| US-5334724-A | Preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| EP-0438691-B1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1994-02-16 | — | — | EP | disclosed |
| EP-0438691-A1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1991-07-31 | — | — | EP | disclosed |
| US-5010201-A | Process for the preparation of substituted 2-chloropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-23 | — | — | US | disclosed |
| EP-0370317-A1 | Process for the preparation of substituted 2-chloropyridines | BAYER AG (DE) | 1990-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GRM5 1/4885NAPRT 2079/4885ALDH1A1 4204/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885NAPRT 2056/4885ALDH1A1 4203/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | GRM5 680/4885NAPRT 2/4885ALDH1A1 117/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885NAPRT 2056/4885ALDH1A1 4203/4885 |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | GRM5 2316/4885NAPRT 1652/4885ALDH1A1 837/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | GRM5 658/4885NAPRT 1519/4885ALDH1A1 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.